Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. EXPO
EXPO logo

EXPO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
70.880
Open
69.800
VWAP
70.07
Vol
436.08K
Mkt Cap
3.45B
Low
69.310
Amount
30.56M
EV/EBITDA(TTM)
24.85
Total Shares
49.25M
EV
3.23B
EV/OCF(TTM)
24.50
P/S(TTM)
6.68
Exponent, Inc., together with its subsidiaries, is a science and engineering consulting firm that provides solutions to complex problems. The Company’s segments include Engineering and Other Scientific and Environmental and Health. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices, primarily in engineering. The Environmental and Health segment provides services in the area of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and their impact on both human health and the environment. It serves clients in chemicals, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation and other sectors of the economy. The Company’s service offerings are provided on a project-by-project basis.
Show More

Events Timeline

(ET)
2026-02-05
16:20:00
Sees Q1 EBITDA at 27.5%-28.5% of Revenues
select
2026-02-05
16:20:00
Exponent Raises Quarterly Cash Dividend to 31 Cents per Share
select
2026-02-05
16:10:00
Company Reports Q4 Revenue of $147.43M, Exceeding Expectations
select

News

NASDAQ.COM
2.0
02-26NASDAQ.COM
EXPO Stock Price Fluctuation and Dividend Dynamics
  • Price Range Analysis: EXPO's 52-week low is $63.81 per share, with a high of $87.88, and the last trade at $72.55 indicates price fluctuations within this range, reflecting market caution regarding its future performance.
  • Technical Indicator Observation: Currently, EXPO's stock price is above its 200-day moving average, suggesting a potential short-term upward trend that may attract investor interest and enhance market liquidity.
  • Dividend Stock Dynamics: EXPO is among nine other dividend stocks that recently crossed above their 200-day moving average, indicating a market preference for high-dividend stocks, which could draw more investors seeking stable returns.
  • Market Sentiment Assessment: Although the current stock price is below the 52-week high, market sentiment remains neutral, prompting investors to monitor upcoming earnings reports and market developments to assess EXPO's long-term investment value.
seekingalpha
9.5
02-06seekingalpha
Exponent, Inc. Reports Strong Q4 2025 Earnings with AI-Driven Growth
  • Significant Revenue Growth: In Q4 2025, Exponent reported an 8% increase in total revenues to $147.4 million, with net income of $24.8 million and diluted earnings per share of $0.49, reflecting strong demand in user research and risk management sectors.
  • Diversified Client Base: CEO Catherine Corrigan highlighted ongoing growth in regulatory and safety consulting for medical devices, particularly in failure analysis for electrification and battery systems, which enhances the company's competitive edge in the market.
  • Optimistic Future Outlook: CFO Richard Schlenker projected high single-digit growth in net revenues for Q1 and full year 2026, with EBITDA margins expected to remain between 27.5% and 28.5%, indicating strong confidence in future growth prospects.
  • Robust Cash Flow: At year-end 2025, cash and cash equivalents stood at $221.9 million, with $131.7 million generated from operations, and the company distributed $14.9 million in dividends while repurchasing $25.1 million in common stock during the quarter, enhancing shareholder returns.
seekingalpha
9.5
02-05seekingalpha
Exponent Reports Q4 2025 Earnings with Positive Outlook
  • Earnings Highlights: Exponent's Q4 2025 GAAP EPS of $0.49 exceeded expectations by $0.02, with revenue of $147.4 million reflecting a 7.7% year-over-year increase, surpassing estimates by $15.41 million, indicating strong market performance.
  • Headcount Growth: The company achieved approximately 4% growth in headcount for 2025, with improved utilization rates in Q4 year-over-year, demonstrating Exponent's effective alignment of resources with market demand, thereby enhancing operational efficiency.
  • Future Outlook: As Exponent enters 2026, it anticipates high-single-digit revenue growth for Q1, with EBITDA projected to be 27.5% to 28.5% of revenues, reflecting a positive outlook on market opportunities and reinforcing confidence in long-term growth.
  • Annual Projections: For the full fiscal year 2026, Exponent expects high-single-digit revenue growth, with EBITDA anticipated to be 27.6% to 28.1% of revenues, further solidifying the company's competitive position and sustainable growth potential.
seekingalpha
9.5
02-05seekingalpha
Exponent Reports Q4 2025 Earnings with Strong Growth Outlook
  • Strong Earnings Report: Exponent's Q4 2025 GAAP EPS of $0.49 exceeded expectations by $0.02, with revenue of $147.4 million reflecting a 7.7% year-over-year increase, surpassing estimates by $15.41 million, indicating robust market performance.
  • Headcount Growth: The company achieved approximately 4% growth in headcount for 2025, with improved resource utilization in Q4 year-over-year, demonstrating Exponent's effective alignment of resources with market demand, thereby enhancing operational efficiency and competitive positioning.
  • Optimistic Future Outlook: As Exponent enters 2026, it anticipates high-single-digit revenue growth for Q1, with EBITDA projected to be 27.5% to 28.5% of revenues before reimbursements, reflecting confidence in market opportunities and sustainable long-term growth.
  • Positive Annual Projections: For the full fiscal year 2026, Exponent expects high-single-digit revenue growth and EBITDA margins of 27.6% to 28.1%, indicating continued strong financial performance and growth potential in the upcoming year.
seekingalpha
9.5
02-04seekingalpha
Exponent Set to Release Q4 Earnings on February 5th
  • Earnings Announcement Date: Exponent is scheduled to announce its Q4 earnings on February 5th after market close, with investors keenly awaiting the results to assess future growth potential.
  • EPS Expectations: The consensus EPS estimate stands at $0.47, reflecting a 2.2% year-over-year increase, indicating stability in the company's profitability.
  • Revenue Forecast Changes: The consensus revenue estimate is $131.99 million, representing a 3.5% year-over-year decline, which suggests a cautious market sentiment regarding the company's revenue growth and may impact investor confidence.
  • Estimate Revision Trends: Over the past three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have experienced one upward and one downward revision, highlighting analysts' differing views on the company's performance.
CNBC
6.0
01-26CNBC
Latest Wall Street Ratings Overview
  • Dutch Bros Rating: Citi initiates coverage of Dutch Bros (BROS) with a Buy rating, citing its proven portability across the U.S. and a fast-growing marketing budget that is expected to drive sales growth over the next 12-24 months, indicating strong growth potential.
  • Tesla Neutral Rating: Goldman Sachs reiterates a Neutral rating on Tesla, expressing concerns that increasing competition in the self-driving sector may limit profit growth, although they remain optimistic about the long-term prospects of its full self-driving and robotaxi operations.
  • Apple Price Target Increase: JPMorgan raises its price target for Apple (AAPL) from $305 to $315 ahead of earnings, anticipating a positive setup for the stock as it approaches a key iPhone product cycle, which could enhance its performance.
  • Meta Upgrade: Rothschild & Co Redburn upgrades Meta from Neutral to Buy, arguing that its potential in AI is not fully appreciated, raising the price target from $740 to $900, making it an opportune time for investors to build positions.
Wall Street analysts forecast EXPO stock price to rise
3 Analyst Rating
Wall Street analysts forecast EXPO stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
81.00
Averages
85.50
High
90.00
Current: 0.000
sliders
Low
81.00
Averages
85.50
High
90.00
UBS
Joshua Chan
Neutral
maintain
$81 -> $85
AI Analysis
2026-02-09
Reason
UBS
Joshua Chan
Price Target
$81 -> $85
AI Analysis
2026-02-09
maintain
Neutral
Reason
UBS analyst Joshua Chan raised the firm's price target on Exponent to $85 from $81 and keeps a Neutral rating on the shares. The Q4 results and 2026 guidance were largely consistent with consensus, but given that guidance typically leans conservative, there could be perceived upside potential through the year against a stock that has de-rated over much of the past year, the analyst tells investors in a research note.
JPMorgan
Tomohiko Sano
Overweight
initiated
$100
2026-01-26
Reason
JPMorgan
Tomohiko Sano
Price Target
$100
2026-01-26
initiated
Overweight
Reason
JPMorgan analyst Tomohiko Sano initiated coverage of Exponent with an Overweight rating and $100 price target, representing 35% upside potential. Exponent is a leader in science and engineering consulting, serving over 2,000 clients across 17 primary practices, the analyst tells investors in a research note. The firm says the company is positioned for a "strong rebound," with its revenue growth projected to accelerate to 9.5% in 2026 and margin expansion as headwinds ease and utilization improves. The stock offers potential upside as Exponent's fundamentals recover and valuation normalizes, contends JPMorgan.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EXPO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Exponent Inc (EXPO.O) is 32.05, compared to its 5-year average forward P/E of 46.54. For a more detailed relative valuation and DCF analysis to assess Exponent Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
46.54
Current PE
32.05
Overvalued PE
55.09
Undervalued PE
37.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
32.81
Current EV/EBITDA
21.35
Overvalued EV/EBITDA
39.06
Undervalued EV/EBITDA
26.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
9.55
Current PS
6.18
Overvalued PS
11.51
Undervalued PS
7.59

Financials

AI Analysis
Annual
Quarterly

Whales Holding EXPO

R
Royce & Associates, LP
Holding
EXPO
+10.25%
3M Return
C
Conestoga Capital Advisors, LLC
Holding
EXPO
+1.92%
3M Return
G
Granite Investment Partners, LLC
Holding
EXPO
-1.01%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Exponent Inc (EXPO) stock price today?

The current price of EXPO is 70.03 USD — it has decreased -0.31

What is Exponent Inc (EXPO)'s business?

Exponent, Inc., together with its subsidiaries, is a science and engineering consulting firm that provides solutions to complex problems. The Company’s segments include Engineering and Other Scientific and Environmental and Health. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices, primarily in engineering. The Environmental and Health segment provides services in the area of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and their impact on both human health and the environment. It serves clients in chemicals, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation and other sectors of the economy. The Company’s service offerings are provided on a project-by-project basis.

What is the price predicton of EXPO Stock?

Wall Street analysts forecast EXPO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXPO is85.50 USD with a low forecast of 81.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Exponent Inc (EXPO)'s revenue for the last quarter?

Exponent Inc revenue for the last quarter amounts to 129.38M USD, increased 4.54

What is Exponent Inc (EXPO)'s earnings per share (EPS) for the last quarter?

Exponent Inc. EPS for the last quarter amounts to 0.49 USD, increased 6.52

How many employees does Exponent Inc (EXPO). have?

Exponent Inc (EXPO) has 1212 emplpoyees as of March 12 2026.

What is Exponent Inc (EXPO) market cap?

Today EXPO has the market capitalization of 3.45B USD.